Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Solid Tumor|Gynecologic Cancer|Breast Cancer|Gastrointestinal Cancer|Lung Cancer
BIOLOGICAL: Engineering Tumor Infiltrating Lymphocytes
Maximal Tolerance Dose, Up to Day 28|Dose Limiting Toxicity, Up to Day 28|Adverse Events, Maximum 360 days
Objective Response Rate, Evaluate the efficacy endpoints of ORR by the investigator with RECIST v1.1 and iRECIST, Every 6 weeks for 12 months|Duration of Response, Evaluate the efficacy endpoints of DoR by the investigator with RECIST v1.1 and iRECIST, Every 6 weeks for 12 months|Disease Control Rate, Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST, Every 6 weeks for 12 months|Progression-Free Survival, Evaluate the efficacy endpoints of PFS by the investigator with RECIST v1.1 and iRECIST, Every 6 weeks for 12 months|Overall Survival, Evaluate the efficacy endpoints of OS by the investigator with RECIST v1.1 and iRECIST, Every 6 weeks for 12 months|Quality of Life Assessment, Evaluate with EORTC QLQ-C30, Every 6 weeks for 12 months
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors